{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T16:52:41Z","timestamp":1789145561783,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Rhythm Pharmaceuticals"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Survivors of sellar\/suprasellar tumors involving hypothalamic structures face a risk of impaired quality of life, including tumor- and\/or treatment-related hypothalamic obesity (TTR-HO) defined as abnormal weight gain resulting in severe persistent obesity due to physical, tumor- and\/or treatment related damage of the hypothalamus. We analyze German claims data to better understand treatment pathways for patients living TTR-HO during the two years following the index surgical treatment. A database algorithm identified patients with TTR-HO in a representative German payer claims database between 2010 and 2021 (n\u2009=\u20095.42 million patients). Claims from 37 patients with TTR-HO were analyzed on a quarterly basis over 2 years. The analysis considered inpatient, outpatient, and prescription data. In the follow-up period, patients with TTR-HO are hospitalized 3.68 times on average; 37% of hospitalizations in year 1 and 31% in year 2 are due to TTR-HO. On average, patients see a general practitioner 12.27 times and various specialists 20.45 times. The need for complex neuroendocrine therapy develops quickly, with most patients having 2\u20133 neuroendocrine prescriptions in any given quarter. The management of patients with TTR-HO requires frequent inpatient and outpatient visits for tumor follow-up and management of incident comorbidities, and most patients with TTR-HO require intense polytherapy.<\/jats:p>","DOI":"10.1038\/s41598-025-85262-1","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T22:23:38Z","timestamp":1736979818000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Treatment of patients with tumor\/treatment-related hypothalamic obesity in the first two years following surgical treatment or radiotherapy"],"prefix":"10.1038","volume":"15","author":[{"given":"Hermann L.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Witte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastian","family":"Surmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Batram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kylie","family":"Braegelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Flume","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Beckhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Touchot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"issue":"Suppl 2","key":"85262_CR1","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/dom.15530","volume":"26","author":"CL Roth","year":"2024","unstructured":"Roth, C. L. & McCormack, S. E. Acquired hypothalamic obesity: A clinical overview and update. Diabetes Obes. Metab. 26(Suppl 2), 34\u201345. https:\/\/doi.org\/10.1111\/dom.15530 (2024).","journal-title":"Diabetes Obes. Metab."},{"issue":"1","key":"85262_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/nrendo.2012.199","volume":"9","author":"VS Malik","year":"2013","unstructured":"Malik, V. S., Willett, W. C. & Hu, F. B. Global obesity: Trends, risk factors and policy implications. Nat. Rev. Endocrinol. 9(1), 13\u201327. https:\/\/doi.org\/10.1038\/nrendo.2012.199 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"issue":"4","key":"85262_CR3","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s13679-018-0320-0","volume":"7","author":"S Weihrauch-Bl\u00fcher","year":"2018","unstructured":"Weihrauch-Bl\u00fcher, S. & Wiegand, S. Risk factors and implications of childhood obesity. Curr. Obes. Rep. 7(4), 254\u2013259. https:\/\/doi.org\/10.1007\/s13679-018-0320-0 (2018).","journal-title":"Curr. Obes. Rep."},{"issue":"7","key":"85262_CR4","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1093\/neuonc\/nov044","volume":"17","author":"AS Sterkenburg","year":"2015","unstructured":"Sterkenburg, A. S. et al. Survival, hypothalamic obesity, and neuropsychological\/psychosocial status after childhood-onset craniopharyngioma: Newly reported long-term outcomes. Neuro Oncol. 17(7), 1029\u20131038. https:\/\/doi.org\/10.1093\/neuonc\/nov044 (2015).","journal-title":"Neuro Oncol."},{"issue":"3","key":"85262_CR5","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.ecl.2020.05.009","volume":"49","author":"HL M\u00fcller","year":"2020","unstructured":"M\u00fcller, H. L. Management of hypothalamic obesity. Endocrinol. Metab. Clin. N. Am. 49(3), 533\u2013552. https:\/\/doi.org\/10.1016\/j.ecl.2020.05.009 (2020).","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"issue":"2","key":"85262_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000496564","volume":"91","author":"MJ Abuzzahab","year":"2019","unstructured":"Abuzzahab, M. J., Roth, C. L. & Shoemaker, A. H. Hypothalamic obesity: Prologue and promise. Horm. Res. Paediatr. 91(2), 128\u2013136. https:\/\/doi.org\/10.1159\/000496564 (2019).","journal-title":"Horm. Res. Paediatr."},{"issue":"1","key":"85262_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41572-019-0125-9","volume":"5","author":"HL M\u00fcller","year":"2019","unstructured":"M\u00fcller, H. L., Merchant, T. E., Warmuth-Metz, M., Martinez-Barbera, J.-P. & Puget, S. Craniopharyngioma. Nat. Rev. Dis. Primers 5(1), 75. https:\/\/doi.org\/10.1038\/s41572-019-0125-9 (2019).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"9","key":"85262_CR8","doi-asserted-by":"publisher","first-page":"5025","DOI":"10.1210\/jc.2004-1874","volume":"90","author":"C Daousi","year":"2005","unstructured":"Daousi, C. et al. Is there a role for ghrelin and peptide-YY in the pathogenesis of obesity in adults with acquired structural hypothalamic damage?. J. Clin. Endocrinol. Metab. 90(9), 5025\u20135030. https:\/\/doi.org\/10.1210\/jc.2004-1874 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"85262_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-022-00351-z","volume":"8","author":"HL M\u00fcller","year":"2022","unstructured":"M\u00fcller, H. L. et al. Hypothalamic syndrome. Nat. Rev. Dis. Primers 8(1), 24. https:\/\/doi.org\/10.1038\/s41572-022-00351-z (2022).","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"1","key":"85262_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.pediatrneurol.2013.09.003","volume":"50","author":"A Rosenfeld","year":"2014","unstructured":"Rosenfeld, A. et al. A review of childhood and adolescent craniopharyngiomas with particular attention to hypothalamic obesity. Pediatr. Neurol. 50(1), 4\u201310. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2013.09.003 (2014).","journal-title":"Pediatr. Neurol."},{"key":"85262_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.876770","volume":"13","author":"M Craven","year":"2022","unstructured":"Craven, M. et al. A survey of patient-relevant outcomes in pediatric craniopharyngioma: Focus on hypothalamic obesity. Front. Endocrinol. (Lausanne) 13, 876770. https:\/\/doi.org\/10.3389\/fendo.2022.876770 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"7","key":"85262_CR12","doi-asserted-by":"publisher","first-page":"3298","DOI":"10.1210\/jc.2003-031751","volume":"89","author":"HL M\u00fcller","year":"2004","unstructured":"M\u00fcller, H. L. et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. J. Clin. Endocrinol. Metab. 89(7), 3298\u20133305. https:\/\/doi.org\/10.1210\/jc.2003-031751 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"85262_CR13","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1530\/EJE-12-0792","volume":"168","author":"CA Steele","year":"2013","unstructured":"Steele, C. A. et al. Hypothalamic obesity: prevalence, associations and longitudinal trends in weight in a specialist adult neuroendocrine clinic. Eur. J. Endocrinol. 168(4), 501\u2013507. https:\/\/doi.org\/10.1530\/EJE-12-0792 (2013).","journal-title":"Eur. J. Endocrinol."},{"issue":"978","key":"85262_CR14","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1136\/pgmj.2006.052241","volume":"83","author":"D Deepak","year":"2007","unstructured":"Deepak, D., Furlong, N. J., Wilding, J. P. H. & MacFarlane, I. A. Cardiovascular disease, hypertension, dyslipidaemia and obesity in patients with hypothalamic-pituitary disease. Postgrad. Med. J. 83(978), 277\u2013280. https:\/\/doi.org\/10.1136\/pgmj.2006.052241 (2007).","journal-title":"Postgrad. Med. J."},{"issue":"1","key":"85262_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1210\/jc.2003-030442","volume":"89","author":"S Srinivasan","year":"2004","unstructured":"Srinivasan, S. et al. Features of the metabolic syndrome after childhood craniopharyngioma. J. Clin. Endocrinol. Metab. 89(1), 81\u201386. https:\/\/doi.org\/10.1210\/jc.2003-030442 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"85262_CR16","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/ijpo.12076","volume":"11","author":"B Haliloglu","year":"2016","unstructured":"Haliloglu, B. et al. Risk factors for mortality caused by hypothalamic obesity in children with hypothalamic tumours. Pediatr. Obes. 11(5), 383\u2013388. https:\/\/doi.org\/10.1111\/ijpo.12076 (2016).","journal-title":"Pediatr. Obes."},{"issue":"11","key":"85262_CR17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/oby.22315","volume":"26","author":"SR Rose","year":"2018","unstructured":"Rose, S. R. et al. Hypothalamic obesity: 4 years of the international registry of hypothalamic obesity disorders. Obesity (Silver Spring) 26(11), 1727\u20131732. https:\/\/doi.org\/10.1002\/oby.22315 (2018).","journal-title":"Obesity (Silver Spring)"},{"issue":"1","key":"85262_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1210\/er.2018-00017","volume":"40","author":"L van Iersel","year":"2019","unstructured":"van Iersel, L. et al. Pathophysiology and individualized treatment of hypothalamic obesity following craniopharyngioma and other suprasellar tumors: A systematic review. Endocr. Rev. 40(1), 193\u2013235. https:\/\/doi.org\/10.1210\/er.2018-00017 (2019).","journal-title":"Endocr. Rev."},{"key":"85262_CR19","doi-asserted-by":"publisher","DOI":"10.4414\/smw.2018.14521","volume":"148","author":"L Andereggen","year":"2018","unstructured":"Andereggen, L. et al. A ten-year follow-up study of treatment outcome of craniopharyngiomas. Swiss Med. Wkly. 148, w14521. https:\/\/doi.org\/10.4414\/smw.2018.14521 (2018).","journal-title":"Swiss Med. Wkly."},{"issue":"10097","key":"85262_CR20","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/S0140-6736(17)31280-1","volume":"390","author":"R Busse","year":"2017","unstructured":"Busse, R., Bl\u00fcmel, M., Knieps, F. & B\u00e4rnighausen, T. Statutory health insurance in Germany: A health system shaped by 135 years of solidarity, self-governance, and competition. Lancet 390(10097), 882\u2013897. https:\/\/doi.org\/10.1016\/S0140-6736(17)31280-1 (2017).","journal-title":"Lancet"},{"key":"85262_CR21","unstructured":"Bundesministerium f\u00fcr Gesundheit. Mitglieder und Versicherte der Gesetzlichen Krankenversicherung (GKV): Statistik uber Versicherte, gegliedert nach Status, Alter, Wohnort und Kassenart; 2020. Available from: URL: https:\/\/www.bundesgesundheitsministerium.de\/themen\/krankenversicherung\/zahlen-und-fakten-zur-krankenversicherung\/mitglieder-und-versicherte."},{"issue":"2","key":"85262_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0034-1396815","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart, E. et al. Gute Praxis Sekund\u00e4rdatenanalyse (GPS): Leitlinien und Empfehlungen. Gesundheitswesen 77(2), 120\u2013126. https:\/\/doi.org\/10.1055\/s-0034-1396815 (2015).","journal-title":"Gesundheitswesen"},{"issue":"5","key":"85262_CR23","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1210\/clinem\/dgac678","volume":"108","author":"AH Shoemaker","year":"2023","unstructured":"Shoemaker, A. H. & Tamaroff, J. Approach to the patient with hypothalamic obesity. J. Clin. Endocrinol. Metab. 108(5), 1236\u20131242. https:\/\/doi.org\/10.1210\/clinem\/dgac678 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"85262_CR24","doi-asserted-by":"publisher","unstructured":"Witte J, Surmann B, Batram M, et al. Hypothalamic obesity: Epidemiology in rare sellar\/suprasellar tumors\u2014A German claims database analysis. J. Neuroendocrinol e13439 (2024). https:\/\/doi.org\/10.1111\/jne.13439","DOI":"10.1111\/jne.13439"},{"issue":"12","key":"85262_CR25","doi-asserted-by":"publisher","first-page":"S214","DOI":"10.1016\/j.jval.2023.09.1103","volume":"26","author":"J Witte","year":"2023","unstructured":"Witte, J. et al. EPH61 epidemiology of tumor-related hypothalamic obesity in Germany\u2014A representative claims data analysis. Value Health 26(12), S214. https:\/\/doi.org\/10.1016\/j.jval.2023.09.1103 (2023).","journal-title":"Value Health"},{"issue":"5","key":"85262_CR26","doi-asserted-by":"publisher","first-page":"e1404","DOI":"10.1210\/clinem\/dgad613","volume":"109","author":"J Beckhaus","year":"2024","unstructured":"Beckhaus, J., Friedrich, C. & M\u00fcller, H. L. Childhood-onset craniopharyngioma\u2014A life-long family burden?. J. Clin. Endocrinol. Metab. 109(5), e1404\u2013e1405. https:\/\/doi.org\/10.1210\/clinem\/dgad613 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"85262_CR27","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1210\/clinem\/dgad488","volume":"109","author":"N Kayadjanian","year":"2023","unstructured":"Kayadjanian, N., Hsu, E. A., Wood, A. M. & Carson, D. S. Caregiver burden and its relationship to health-related quality of life in craniopharyngioma survivors. J. Clin. Endocrinol. Metab. 109(1), e76\u2013e87. https:\/\/doi.org\/10.1210\/clinem\/dgad488 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"85262_CR28","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1093\/rheumatology\/keaa289","volume":"60","author":"L Fardet","year":"2021","unstructured":"Fardet, L., Nazareth, I. & Petersen, I. Long-term systemic glucocorticoid therapy and weight gain: a population-based cohort study. Rheumatology (Oxford) 60(3), 1502\u20131511. https:\/\/doi.org\/10.1093\/rheumatology\/keaa289 (2021).","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"85262_CR29","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1467-789X.2011.00969.x","volume":"13","author":"GD Eslick","year":"2012","unstructured":"Eslick, G. D. Gastrointestinal symptoms and obesity: A meta-analysis. Obes. Rev. 13(5), 469\u2013479. https:\/\/doi.org\/10.1111\/j.1467-789X.2011.00969.x (2012).","journal-title":"Obes. Rev."},{"issue":"1","key":"85262_CR30","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1001\/jama.290.1.66","volume":"290","author":"M Nilsson","year":"2003","unstructured":"Nilsson, M., Johnsen, R., Ye, W., Hveem, K. & Lagergren, J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA 290(1), 66\u201372. https:\/\/doi.org\/10.1001\/jama.290.1.66 (2003).","journal-title":"JAMA"},{"key":"85262_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.846880","volume":"13","author":"P Dimitri","year":"2022","unstructured":"Dimitri, P. Treatment of acquired hypothalamic obesity: Now and the future. Front. Endocrinol. (Lausanne) 13, 846880. https:\/\/doi.org\/10.3389\/fendo.2022.846880 (2022).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"85262_CR32","doi-asserted-by":"publisher","DOI":"10.1530\/endoabs.90.P134","author":"CL Roth","year":"2023","unstructured":"Roth, C. L. et al. Efficacy and safety analysis of setmelanotide as a novel treatment for hypothalamic obesity. EJEA https:\/\/doi.org\/10.1530\/endoabs.90.P134 (2023).","journal-title":"EJEA"},{"issue":"7","key":"85262_CR33","doi-asserted-by":"publisher","DOI":"10.1111\/ijpo.12903","volume":"17","author":"AA Rydin","year":"2022","unstructured":"Rydin, A. A. et al. Novel clinical algorithm for hypothalamic obesity in youth with brain tumours and factors associated with excess weight gain. Pediatr. Obes. 17(7), e12903. https:\/\/doi.org\/10.1111\/ijpo.12903 (2022).","journal-title":"Pediatr. Obes."},{"issue":"4","key":"85262_CR34","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1210\/jc.2013-3631","volume":"99","author":"KCJ Yuen","year":"2014","unstructured":"Yuen, K. C. J. et al. Primary treatment regimen and diabetes insipidus as predictors of health outcomes in adults with childhood-onset craniopharyngioma. J. Clin. Endocrinol. Metab. 99(4), 1227\u20131235. https:\/\/doi.org\/10.1210\/jc.2013-3631 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"85262_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1530\/EC-19-0074","volume":"8","author":"A Bogusz","year":"2019","unstructured":"Bogusz, A. et al. Posterior hypothalamus-sparing surgery improves outcome after childhood craniopharyngioma. Endocr. Connect 8(5), 481\u2013492. https:\/\/doi.org\/10.1530\/EC-19-0074 (2019).","journal-title":"Endocr. Connect"},{"issue":"1","key":"85262_CR36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1530\/EJE-17-0707","volume":"178","author":"M Wijnen","year":"2018","unstructured":"Wijnen, M. et al. Excess morbidity and mortality in patients with craniopharyngioma: a hospital-based retrospective cohort study. Eur. J. Endocrinol. 178(1), 93\u2013102. https:\/\/doi.org\/10.1530\/EJE-17-0707 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"85262_CR37","unstructured":"Reber KC, Angelow A, Schmidt CO, Baumeister S, Chenot J-F. Externe Diagnosevalidierung von Routinedaten am Beispiel ausgew\u00e4hlter kardiovaskul\u00e4rer Risikofaktoren. German Medical Science GMS Publishing House; 2015."},{"issue":"2","key":"85262_CR38","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.healthpol.2016.01.007","volume":"120","author":"K Kreis","year":"2016","unstructured":"Kreis, K., Neubauer, S., Klora, M., Lange, A. & Zeidler, J. Status and perspectives of claims data analyses in Germany\u2014A systematic review. Health Policy 120(2), 213\u2013226. https:\/\/doi.org\/10.1016\/j.healthpol.2016.01.007 (2016).","journal-title":"Health Policy"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85262-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85262-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T22:23:44Z","timestamp":1736979824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-85262-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["85262"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-85262-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,16]]},"assertion":[{"value":"27 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hermann L. M\u00fcller has received reimbursement of participation fees for scientific meetings and continuing medical education events from the following companies: Ferring, Lilly, Pfizer, Sandoz\/Hexal, Novo Nordisk, IPSEN, Rhythm Pharmaceuticals, and Merck Serono. He has received reimbursement of travel expenses from IPSEN, Rhythm Pharmaceuticals, and lecture honoraria from Pfizer.  Julia Beckhaus and Carsten Friedrich have nothing to disclose.  Nicolas Touchot is employed by and owns shares of Rhythm Pharmaceuticals. Mathias Flume is the founder and owner of GeneAccess GmbH and employed by Kassen\u00e4rztliche Vereinigung Westfalen-Lippe. GeneAccess GmbH received payments from Rhythm Pharmaceuticals. Julian Witte and Manuel Batram are employed by Vandage and own shares of Vandage GmbH.  Kylie Braegelmann and Bastian Surmann are employed by Vandage.  Vandage has received payments from Rhythm Pharmaceuticals, Alexion, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Moderna, Merck & Co., Pfizer, PTC Therapeutics, Sanofi Pasteur, Seqirus, Viatris and consulting fees and grants from AOK Rheinland\/Hamburg, BARMER, DAK-Gesundheit, German G-BA, and Techniker Krankenkasse. There are no other competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No patient data were collected for this study. The study protocol, which exclusively provides for the use of previously pseudonymized data, was drawn up in accordance with the HARPER specifications (\n                      \n                      ) and approved by all authors. According to German data protections within \u00a7 75 Sozialgesetzbuch (SGB) X, the guidelines and recommendations of the Good Practice of Secondary Data Analysis (\n                      \n                      ), and the complete pseudonymization of the data by the data holder, ethical approval or informed consent were not required for this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"2118"}}